Atypical  ||| S:0 E:9 ||| FW
hemolytic  ||| S:9 E:19 ||| FW
uremic  ||| S:19 E:26 ||| FW
syndrome  ||| S:26 E:35 ||| FW
( ||| S:35 E:36 ||| -LRB-
aHUS ||| S:36 E:40 ||| NNP
) ||| S:40 E:41 ||| -RRB-
:  ||| S:41 E:43 ||| :
making  ||| S:43 E:50 ||| VBG
the  ||| S:50 E:54 ||| DT
diagnosis  ||| S:54 E:64 ||| FW
Atypical  ||| S:64 E:73 ||| FW
hemolytic  ||| S:73 E:83 ||| FW
uremic  ||| S:83 E:90 ||| FW
syndrome  ||| S:90 E:99 ||| FW
( ||| S:99 E:100 ||| -LRB-
aHUS ||| S:100 E:104 ||| NNP
)  ||| S:104 E:106 ||| -RRB-
is  ||| S:106 E:109 ||| VBZ
a  ||| S:109 E:111 ||| DT
major  ||| S:111 E:117 ||| JJ
thrombotic  ||| S:117 E:128 ||| JJ
microangiopathy  ||| S:128 E:144 ||| NNS
( ||| S:144 E:145 ||| -LRB-
TMA ||| S:145 E:148 ||| NNP
) ||| S:148 E:149 ||| -RRB-
.  ||| S:149 E:151 ||| .
A  ||| S:151 E:153 ||| DT
TMA  ||| S:153 E:157 ||| NNP
is  ||| S:157 E:160 ||| VBZ
recognized  ||| S:160 E:171 ||| VBN
by  ||| S:171 E:174 ||| IN
the  ||| S:174 E:178 ||| DT
laboratory  ||| S:178 E:189 ||| NN
signs  ||| S:189 E:195 ||| NNS
of  ||| S:195 E:198 ||| IN
microangiopathic  ||| S:198 E:215 ||| JJ
hemolysis ||| S:215 E:224 ||| NN
,  ||| S:224 E:226 ||| ,
as  ||| S:226 E:229 ||| RB
indicated  ||| S:229 E:239 ||| VBN
by  ||| S:239 E:242 ||| IN
schistocytes ||| S:242 E:254 ||| NN
,  ||| S:254 E:256 ||| ,
elevated  ||| S:256 E:265 ||| VBD
lactate  ||| S:265 E:273 ||| JJ
dehydrogenase ||| S:273 E:286 ||| NN
,  ||| S:286 E:288 ||| ,
low  ||| S:288 E:292 ||| JJ
haptoglobin ||| S:292 E:303 ||| NN
,  ||| S:303 E:305 ||| ,
and  ||| S:305 E:309 ||| CC
low  ||| S:309 E:313 ||| JJ
hemoglobin ||| S:313 E:323 ||| NN
,  ||| S:323 E:325 ||| ,
plus  ||| S:325 E:330 ||| CC
thrombocytopenia  ||| S:330 E:347 ||| NNS
and  ||| S:347 E:351 ||| CC
accompanying  ||| S:351 E:364 ||| JJ
signs  ||| S:364 E:370 ||| NNS
and  ||| S:370 E:374 ||| CC
symptoms  ||| S:374 E:383 ||| NNS
of  ||| S:383 E:386 ||| IN
organ  ||| S:386 E:392 ||| JJ
system  ||| S:392 E:399 ||| NN
involvement.  ||| S:399 E:412 ||| CD
aHUS  ||| S:412 E:417 ||| JJ
results  ||| S:417 E:425 ||| NNS
from  ||| S:425 E:430 ||| IN
chronic ||| S:430 E:437 ||| NN
,  ||| S:437 E:439 ||| ,
uncontrolled  ||| S:439 E:452 ||| JJ
activity  ||| S:452 E:461 ||| NN
of  ||| S:461 E:464 ||| IN
the  ||| S:464 E:468 ||| DT
alternative  ||| S:468 E:480 ||| JJ
complement  ||| S:480 E:491 ||| JJ
pathway ||| S:491 E:498 ||| NN
.  ||| S:498 E:500 ||| .
In  ||| S:500 E:503 ||| IN
most  ||| S:503 E:508 ||| JJS
patients ||| S:508 E:516 ||| NNS
,  ||| S:516 E:518 ||| ,
this  ||| S:518 E:523 ||| DT
defect  ||| S:523 E:530 ||| NN
is  ||| S:530 E:533 ||| VBZ
related  ||| S:533 E:541 ||| VBN
to  ||| S:541 E:544 ||| TO
a  ||| S:544 E:546 ||| DT
genetic  ||| S:546 E:554 ||| JJ
deficiency  ||| S:554 E:565 ||| NN
in  ||| S:565 E:568 ||| IN
one  ||| S:568 E:572 ||| CD
or  ||| S:572 E:575 ||| CC
more  ||| S:575 E:580 ||| RBR
soluble  ||| S:580 E:588 ||| JJ
and ||| S:588 E:591 ||| CC
/ ||| S:591 E:592 ||| NNP
or  ||| S:592 E:595 ||| CC
membrane-bound  ||| S:595 E:610 ||| JJ
complement  ||| S:610 E:621 ||| JJ
regulatory  ||| S:621 E:632 ||| JJ
proteins ||| S:632 E:640 ||| NNS
.  ||| S:640 E:642 ||| .
Complement  ||| S:642 E:653 ||| JJ
factor  ||| S:653 E:660 ||| NN
H  ||| S:660 E:662 ||| NNP
is  ||| S:662 E:665 ||| VBZ
most  ||| S:665 E:670 ||| RBS
frequently  ||| S:670 E:681 ||| RB
implicated ||| S:681 E:691 ||| VBN
.  ||| S:691 E:693 ||| .
Clinically ||| S:693 E:703 ||| NNP
,  ||| S:703 E:705 ||| ,
aHUS  ||| S:705 E:710 ||| NNP
is  ||| S:710 E:713 ||| VBZ
often  ||| S:713 E:719 ||| RB
indistinguishable  ||| S:719 E:737 ||| VBN
from  ||| S:737 E:742 ||| IN
the  ||| S:742 E:746 ||| DT
other  ||| S:746 E:752 ||| JJ
TMAs ||| S:752 E:756 ||| NN
:  ||| S:756 E:758 ||| :
Shiga  ||| S:758 E:764 ||| NNP
toxinâ€“producing  ||| S:764 E:780 ||| NNP
Escherichia  ||| S:780 E:792 ||| NNP
coli  ||| S:792 E:797 ||| NNS
( ||| S:797 E:798 ||| -LRB-
STEC ||| S:798 E:802 ||| NNP
)  ||| S:802 E:804 ||| -RRB-
hemolytic  ||| S:804 E:814 ||| JJ
uremic  ||| S:814 E:821 ||| JJ
syndrome  ||| S:821 E:830 ||| NN
and  ||| S:830 E:834 ||| CC
thrombotic  ||| S:834 E:845 ||| FW
thrombocytopenic  ||| S:845 E:862 ||| FW
purpura  ||| S:862 E:870 ||| FW
( ||| S:870 E:871 ||| -LRB-
TTP ||| S:871 E:874 ||| NNP
) ||| S:874 E:875 ||| -RRB-
.  ||| S:875 E:877 ||| .
TTP  ||| S:877 E:881 ||| NNP
and  ||| S:881 E:885 ||| CC
aHUS  ||| S:885 E:890 ||| NNS
are  ||| S:890 E:894 ||| VBP
associated  ||| S:894 E:905 ||| VBN
with  ||| S:905 E:910 ||| IN
high  ||| S:910 E:915 ||| JJ
morbidity  ||| S:915 E:925 ||| NN
and  ||| S:925 E:929 ||| CC
mortality.  ||| S:929 E:940 ||| NNP
aHUS  ||| S:940 E:945 ||| NNP
has  ||| S:945 E:949 ||| VBZ
a  ||| S:949 E:951 ||| DT
distinct  ||| S:951 E:960 ||| JJ
pathology  ||| S:960 E:970 ||| NN
from  ||| S:970 E:975 ||| IN
TTP ||| S:975 E:978 ||| NNP
.  ||| S:978 E:980 ||| .
In  ||| S:980 E:983 ||| IN
nearly  ||| S:983 E:990 ||| RB
all  ||| S:990 E:994 ||| DT
patients ||| S:994 E:1002 ||| NNS
,  ||| S:1002 E:1004 ||| ,
aHUS  ||| S:1004 E:1009 ||| NNP
can  ||| S:1009 E:1013 ||| MD
be  ||| S:1013 E:1016 ||| VB
distinguished  ||| S:1016 E:1030 ||| VBN
from  ||| S:1030 E:1035 ||| IN
TTP  ||| S:1035 E:1039 ||| NNP
on  ||| S:1039 E:1042 ||| IN
the  ||| S:1042 E:1046 ||| DT
basis  ||| S:1046 E:1052 ||| NN
of  ||| S:1052 E:1055 ||| IN
an  ||| S:1055 E:1058 ||| DT
ADAMTS13  ||| S:1058 E:1067 ||| NNP
( ||| S:1067 E:1068 ||| -LRB-
a  ||| S:1068 E:1070 ||| DT
disintegrin  ||| S:1070 E:1082 ||| NN
and  ||| S:1082 E:1086 ||| CC
metalloproteinase  ||| S:1086 E:1104 ||| NN
with  ||| S:1104 E:1109 ||| IN
a  ||| S:1109 E:1111 ||| DT
thrombospondin  ||| S:1111 E:1126 ||| JJ
type  ||| S:1126 E:1131 ||| NN
1  ||| S:1131 E:1133 ||| CD
motif ||| S:1133 E:1138 ||| NN
,  ||| S:1138 E:1140 ||| ,
member  ||| S:1140 E:1147 ||| NN
13 ||| S:1147 E:1149 ||| CD
)  ||| S:1149 E:1151 ||| -RRB-
enzyme  ||| S:1151 E:1158 ||| JJ
activity  ||| S:1158 E:1167 ||| NN
measurement ||| S:1167 E:1178 ||| NN
.  ||| S:1178 E:1180 ||| .
It  ||| S:1180 E:1183 ||| PRP
is  ||| S:1183 E:1186 ||| VBZ
essential  ||| S:1186 E:1196 ||| JJ
that  ||| S:1196 E:1201 ||| IN
aHUS  ||| S:1201 E:1206 ||| JJ
and  ||| S:1206 E:1210 ||| CC
TTP  ||| S:1210 E:1214 ||| NNP
be  ||| S:1214 E:1217 ||| VB
differentiated  ||| S:1217 E:1232 ||| VBN
quickly ||| S:1232 E:1239 ||| RB
,  ||| S:1239 E:1241 ||| ,
as  ||| S:1241 E:1244 ||| IN
they  ||| S:1244 E:1249 ||| PRP
require  ||| S:1249 E:1257 ||| VBP
markedly  ||| S:1257 E:1266 ||| RB
divergent  ||| S:1266 E:1276 ||| JJ
treatments ||| S:1276 E:1286 ||| NNS
.  ||| S:1286 E:1288 ||| .
The  ||| S:1288 E:1292 ||| DT
standard  ||| S:1292 E:1301 ||| JJ
treatment  ||| S:1301 E:1311 ||| NN
for  ||| S:1311 E:1315 ||| IN
TTP  ||| S:1315 E:1319 ||| NNP
is  ||| S:1319 E:1322 ||| VBZ
plasma  ||| S:1322 E:1329 ||| JJ
exchange ||| S:1329 E:1337 ||| NN
,  ||| S:1337 E:1339 ||| ,
a  ||| S:1339 E:1341 ||| DT
therapy  ||| S:1341 E:1349 ||| NN
that  ||| S:1349 E:1354 ||| WDT
has  ||| S:1354 E:1358 ||| VBZ
no  ||| S:1358 E:1361 ||| DT
role  ||| S:1361 E:1366 ||| NN
for  ||| S:1366 E:1370 ||| IN
patients  ||| S:1370 E:1379 ||| NNS
with  ||| S:1379 E:1384 ||| IN
a  ||| S:1384 E:1386 ||| DT
diagnosis  ||| S:1386 E:1396 ||| NN
of  ||| S:1396 E:1399 ||| IN
aHUS  ||| S:1399 E:1404 ||| JJ
established  ||| S:1404 E:1416 ||| VBN
by  ||| S:1416 E:1419 ||| IN
ADAMTS13  ||| S:1419 E:1428 ||| CD
activity  ||| S:1428 E:1437 ||| NN
levels ||| S:1437 E:1443 ||| NNS
.  ||| S:1443 E:1445 ||| .
